Panitumumab (ABX-EGF) is a monoclonal antibody primarily used in the treatment of metastatic colorectal cancer. It is specifically indicated for patients whose tumors express the epidermal growth factor receptor (EGFR), have wild-type KRAS (no KRAS mutations), and have not responded to other chemotherapy treatments. The drug works by binding to the EGFR on the surface of cancer cells, inhibiting its activity and signaling pathways, thereby slowing down the growth and spread of cancer cells. It is often administered as a monotherapy or in combination with other chemotherapeutic agents. Panitumumab is given intravenously and requires careful monitoring for potential side effects, such as skin reactions, electrolyte imbalances, diarrhea, and increased infection risk. Its targeted approach helps in improving the quality of life and survival rates for patients with advanced colorectal cancer.